Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel.

Hagihara K, Kazui M, Kurihara A, Kubota K, Ikeda T.

Drug Metab Dispos. 2011 Feb;39(2):208-14. doi: 10.1124/dmd.110.035196. Epub 2010 Oct 29.

PMID:
21036950
[PubMed - indexed for MEDLINE]
Free Article
2.

The intestine as an important contributor to prasugrel active metabolite formation in vivo.

Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Izumi T, Ikeda T, Kurihara A.

Drug Metab Dispos. 2011 Apr;39(4):565-70. doi: 10.1124/dmd.110.035956. Epub 2010 Dec 28.

PMID:
21189331
[PubMed - indexed for MEDLINE]
Free Article
3.

Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite.

Hagihara K, Kazui M, Kurihara A, Iwabuchi H, Ishikawa M, Kobayashi H, Tanaka N, Okazaki O, Farid NA, Ikeda T.

Drug Metab Dispos. 2010 Jun;38(6):898-904. doi: 10.1124/dmd.110.032086. Epub 2010 Mar 12.

PMID:
20228231
[PubMed - indexed for MEDLINE]
Free Article
4.

Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate.

Hagihara K, Kazui M, Kurihara A, Ikeda T, Izumi T.

Drug Metab Dispos. 2012 Sep;40(9):1854-9. doi: 10.1124/dmd.112.045914. Epub 2012 Jun 25.

PMID:
22733806
[PubMed - indexed for MEDLINE]
Free Article
5.

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ.

Drug Metab Dispos. 2006 Apr;34(4):600-7. Epub 2006 Jan 13.

PMID:
16415119
[PubMed - indexed for MEDLINE]
Free Article
6.

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ, Kazui M, Farid NA.

Drug Metab Dispos. 2008 Jul;36(7):1227-32. doi: 10.1124/dmd.107.020248. Epub 2008 Mar 27.

PMID:
18372401
[PubMed - indexed for MEDLINE]
Free Article
7.

A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.

Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T.

Drug Metab Dispos. 2009 Nov;37(11):2145-52. doi: 10.1124/dmd.109.028498. Epub 2009 Aug 24.

PMID:
19704027
[PubMed - indexed for MEDLINE]
Free Article
8.

Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.

Chen CH, Yang JC, Uang YS, Lin CJ.

Biopharm Drug Dispos. 2012 Jul;33(5):278-83. doi: 10.1002/bdd.1795. Epub 2012 Jun 29.

PMID:
22623337
[PubMed - indexed for MEDLINE]
9.

The disposition of prasugrel, a novel thienopyridine, in humans.

Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ.

Drug Metab Dispos. 2007 Jul;35(7):1096-104. Epub 2007 Apr 2.

PMID:
17403916
[PubMed - indexed for MEDLINE]
Free Article
10.
11.

Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.

Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Takahashi M, Kurihara A, Okazaki O, Farid NA, Ikeda T.

Xenobiotica. 2009 Mar;39(3):218-26. doi: 10.1080/00498250802650077.

PMID:
19280520
[PubMed - indexed for MEDLINE]
12.

Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring.

Dansette PM, Rosi J, Debernardi J, Bertho G, Mansuy D.

Chem Res Toxicol. 2012 May 21;25(5):1058-65. doi: 10.1021/tx3000279. Epub 2012 Apr 18.

PMID:
22482514
[PubMed - indexed for MEDLINE]
13.

Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel.

Dansette PM, Thébault S, Bertho G, Mansuy D.

Chem Res Toxicol. 2010 Jul 19;23(7):1268-74. doi: 10.1021/tx1001332.

PMID:
20557086
[PubMed - indexed for MEDLINE]
14.

[Prasugrel, a new thienopyridine].

Schrör K, Huber K.

Hamostaseologie. 2007 Dec;27(5):351-5. German.

PMID:
18060245
[PubMed - indexed for MEDLINE]
15.

Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.

Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA, Asai F.

Thromb Haemost. 2005 Sep;94(3):593-8.

PMID:
16268477
[PubMed - indexed for MEDLINE]
16.

Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor.

Algaier I, Jakubowski JA, Asai F, von Kügelgen I.

J Thromb Haemost. 2008 Nov;6(11):1908-14. doi: 10.1111/j.1538-7836.2008.03136.x. Epub 2008 Aug 22.

PMID:
18752581
[PubMed - indexed for MEDLINE]
17.

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Small DS, Farid NA, Li YG, Ernest CS 2nd, Payne CD, Salazar DE, Winters KJ.

Curr Med Res Opin. 2008 Aug;24(8):2251-7. doi: 10.1185/03007990802205985.

PMID:
18786302
[PubMed - indexed for MEDLINE]
18.

Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.

Dobesh PP.

Pharmacotherapy. 2009 Sep;29(9):1089-102. doi: 10.1592/phco.29.9.1089.

PMID:
19698014
[PubMed - indexed for MEDLINE]
19.

Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients.

Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J.

Metabolism. 2011 Nov;60(11):1584-9. doi: 10.1016/j.metabol.2011.03.015. Epub 2011 May 6.

PMID:
21550074
[PubMed - indexed for MEDLINE]
20.

Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.

Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, Desmeules J.

Curr Drug Metab. 2010 Oct;11(8):667-77. Review.

PMID:
20942779
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk